MENU
IKT
Stock ticker: NASDAQ
PRICE
CHANGE
CAPITALIZATION
Inhibikase Therapeutics (IKT) Ownership - Who owns Inhibikase Therapeutics?
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson’s disease (PD), Parkinson’s-related disorders and other diseases of the Abelson Tyrosine Kinases... Show more
Profile
Industry
N/A
Address
3350 Riverwood Parkway SE
Phone
+1 678 392-3419
Employees
14
Web
https://www.inhibikase.com
Details
Group
Domestic Stock Funds
Category
Biotechnology
Capitalization
124.15M
P/E Ratio
N/A
Total Cash
93.18M
Projected Growth
N/A
Total Debt
74.77K
Revenue
N/A
Risk (Beta)
0.77
Dividend Yield
N/A
Total Cash/Share
1.25
Total Debt/Equity
N/A
Revenue/Share
null USD as % of share price
Fundamentals
IKT
Capitalization
124M
P/E Ratio
N/A
Risk (Beta)
0.77
Dividend Yield
N/A
Total Cash
93.2M
Total Cash/Share
1.25
Total Debt
74.8K
Total Debt/Equity
N/A
Projected Growth (PEG Ratio)
N/A
Revenue/Share (as % of the share price)
0%
Revenue
0
ROE
N/A
Book Value
85.7M
P/B Ratio
1.44
Cash Flow
N/A
Earnings
-0.58
Average Daily Volume YTD
N/A
Common Shares Outstanding - Security Level
74.3K
Current Ratio
11.01
Current Revenue Per Employee
N/A
Dividends Per Share - Security
N/A
EBITDA
-39.54M
Float
N/A
Float - Current
N/A
Gross Income Margin
N/A
Revenue To Assets
-69.39
Shares Held By Institutions
113M
Shares Outstanding - Current
74.3M
Total Liabilities
8.55M
Total Volume MTD
N/A
Value
1
Gain YTD
-48.615
View a ticker or compare two or three
VS
VS
Show more...
Interact to see
Advertisement
Advertisement
A.I.Advisor
published price charts
A.I. Advisor
published General Information
General Information
Industry Biotechnology
Profile
Fundamentals
Details
Industry
N/A
Address
3350 Riverwood Parkway SE
Phone
+1 678 392-3419
Employees
14
Web
https://www.inhibikase.com